A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)
Completed
Pfizer
Phase 1
2009-10-16
Ertugliflozin (PF-04971729, MK-8835) is a new compound proposed for the treatment of Type 2
diabetes mellitus. The primary purpose of this study is to evaluate the safety and
tolerability along with the pharmacokinetics of single escalating doses of ertugliflozin
under fed and fasted conditions in healthy volunteers.
A Single Escalating Dose Study Of Ertugliflozin (PF-04971729, MK-8835) Under Fed and Fasted Conditons In Healthy Volunteers (MK-8835-036)
Completed
Merck Sharp & Dohme Corp.
Phase 1
2009-10-16
Ertugliflozin (PF-04971729, MK-8835) is a new compound proposed for the treatment of Type 2
diabetes mellitus. The primary purpose of this study is to evaluate the safety and
tolerability along with the pharmacokinetics of single escalating doses of ertugliflozin
under fed and fasted conditions in healthy volunteers.
A Multiple Dose Study Of Ertugliflozin (PF-04971729, MK-8835) In Otherwise Healthy Overweight And Obese Volunteers (MK-8835-037)
Completed
Pfizer
Phase 1
2009-12-14
Ertugliflozin (PF-04971729, MK-8835) is under development for the treatment of Type 2
Diabetes. The primary purpose of this trial is to evaluate the safety and tolerability,
pharmacokinetics and pharmacodynamics, of multiple oral doses of ertugliflozin.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
